Bayer ’s Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention (for specialized target groups only)

PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news